Tag: CathVision

Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst

Series of Clinical Studies Highlight Advantages of ECGenius System and CARDIALYTICS Suite of Algorithms COPENHAGEN, Denmark, April 17, 2023 /PRNewswire/ —  CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced initial patient enrollment of a follow-on clinical study to demonstrate the value […]

CathVision Announces Key Milestones in Advance of ECGenius Commercial Launch

ECGenius System & CARDIALYTICS Suite Recognized as Critical to the Evolution of Electrophysiology COPENHAGEN, Denmark, March 28, 2023 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision-making in the EP lab, is proud to announce the achievement of significant milestones demonstrating both the clinical and commercial […]

CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic Tools COPENHAGEN, Denmark, Nov. 2, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in […]

CathVision Announces Close Of $7.2 Million Financing Round

Funding Will Accelerate Commercialization of the ECGenius™ System and Expand Development of Analytic Modules COPENHAGEN, Denmark, Aug. 17, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the company has secured $7.2 million in funding from existing investors. The financing […]

CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology

ECGenius Sets a New Standard for ECG Signal Detection, Interpretation and Therapy Support COPENHAGEN, Denmark , May 4, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the ECGenius EP Recording System. ECGenius, the […]

CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology

University of Vermont Medical Center Initiates Evaluation of the ECGenius System as CathVision Prepares for U.S. Launch COPENHAGEN, Denmark, April 26, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to guide and enhance cardiac ablation therapy through the acquisition of low-noise, high-fidelity electrograms, today announced the completion of patient […]

CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study

Researchers to Examine Efficacy of Using AI Algorithm to Confirm Pulmonary Vein Isolation COPENHAGEN, Denmark and MINNETONKA, Minn., Oct. 26, 2021 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions in EP recording technology, today announced the first patient enrollments in the PVISION multicenter clinical study. The newly launched trial will investigate the […]

CathVision adds US profile to its Board of Directors

COPENHAGEN, Denmark, March 16, 2021 /PRNewswire/ — CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors. Meghna Eichelberger, Partner and Associate Director of Medical Technologies, at The Boston Consulting Group (BCG), has joined CathVision’s Board […]

CathVision clinical results to be presented at the AF Symposium

COPENHAGEN, Denmark, Jan. 29, 2021 /PRNewswire/ — CathVision ApS, a medical device company developing a novel cardiac electrophysiology system and artificial intelligence platform to guide ablation therapy for heart rhythm disorders, is featured at the 26th annual international AF Symposium, held online January 29-31st. On January 30th, Professor Josef Kautzner, Institute of Cardiology and Experimental Medicine […]

Cathvision Completes New Investment Round of a Total 13M Euro

COPENHAGEN, May 19, 2020 /PRNewswire/ — CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total 13M euro. Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete […]